+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating whether intismeran autogene, given with pembrolizumab and chemotherapy, can improve outcomes for people with metastatic treatment-naive squamous non-small cell lung cancer NSCLC. This study compares the combination of intismeran autogene with pembrolizumab and chemotherapy against a placebo with pembrolizumab and chemotherapy to see if it helps patients live longer without the cancer growing or spreading. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Merck Sharp & Dohme LLC. Participants receive treatments in two phases induction and maintenance. During the induction phase, pembrolizumab is given by intravenous infusion every six weeks combined with a platinum-based chemotherapy regimen and either paclitaxel or nab-paclitaxel. Intismeran autogene or placebo injections are administered intramuscularly on specific days during the induction phase. In the maintenance phase, pembrolizumab continues every six weeks, and intismeran autogene or placebo injections are given every three weeks for up to seven doses. Participants will be closely monitored throughout the study with regular assessments including scans, laboratory tests, and evaluations of their cancers response and overall health. The main outcomes measured are progression-free survival and overall survival over approximately 32 to 42 months. Secondary outcomes include response rates, duration of response, and the occurrence of side effects. The study aims to collect comprehensive data to understand the effects and safety of the study treatment combination compared to placebo.

Age: 18Years +All GendersPhase 2
55 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.

Age: 18Years +All GendersPhase 3
180 locations
R

Actively Recruiting

Researchers are investigating whether adding intismeran autogene to pembrolizumab after surgery helps prevent cancer from returning in people with non-small cell lung cancer NSCLC whose tumors did not fully respond to treatment before surgery. This randomized phase 3 clinical trial compares pembrolizumab combined with intismeran autogene versus pembrolizumab with placebo in participants with resectable Stage II to IIIB NSCLC. The study focuses on individuals who have not achieved a complete pathological response after neoadjuvant therapy, aiming to improve disease-free survival. Participants receive neoadjuvant treatment consisting of pembrolizumab via intravenous infusion every 3 weeks for up to 4 cycles, combined with background chemotherapy chosen by the investigator. After surgery, the adjuvant treatment phase involves pembrolizumab given intravenously every 6 weeks for up to 7 cycles, plus either intismeran autogene or placebo administered by intramuscular injection every 3 weeks for up to 9 doses. The neoadjuvant phase lasts about 12 weeks, and the adjuvant phase extends up to approximately 42 weeks. During the study, participants will have regular assessments including monitoring for disease recurrence, survival, and quality of life using standardized questionnaires. Researchers will track adverse events and treatment tolerability throughout the trial, with follow-up lasting up to over 8 years to evaluate long-term outcomes. The main measurement is disease-free survival, with additional evaluations of overall survival, distant metastasis-free survival, and lung cancer-specific survival, along with patient-reported quality of life and safety data.

Age: 18Years +All GendersPhase 3
245 locations
S

Actively Recruiting

Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.

Age: 18Years +All GendersPhase 3
364 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of AZD4144 in adults aged 18 to 80 years with sepsis-associated acute kidney injury. This Phase IIa, randomized, double-blind, placebo-controlled study includes participants who have sepsis caused by suspected or confirmed bacterial infection requiring vasopressor or inotrope treatment and developed acute kidney injury within 72 hours of sepsis onset. Participants will be randomly assigned to receive either intravenous AZD4144 or a matching placebo once daily for a fixed treatment period. During this time, daily safety monitoring and collection of blood and urine samples will occur. After treatment, participants will continue to be monitored daily while hospitalized and will have up to two follow-up visits after discharge to assess safety and kidney function. Throughout the study, researchers will measure kidney function markers such as 24-hour creatinine clearance and other related outcomes. Additional assessments include monitoring days alive without kidney replacement therapy, mechanical ventilation, or hospitalization over approximately 30 days. Safety and tolerability will be closely observed during and after treatment, with the total participation spanning screening, treatment, hospitalization monitoring, and post-discharge follow-up visits.

Age: 18Years - 80YearsAll GendersPhase 2
74 locations
E

Actively Recruiting

This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.

Age: 18Years +All GendersPhase 3
473 locations
S

Actively Recruiting

Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.

Age: 18Years +All Genders
849 locations
C

Actively Recruiting

Healthy Volunteer

This research aims to compare how much glucoraphanin and sulforaphane from three different broccoli extract supplements are absorbed into the body and excreted in urine. The study involves generally healthy adults aged 18 to 60 years who do not smoke or are not pregnant or lactating. These compounds, naturally found in cruciferous vegetables, are thought to have health benefits including potential cancer prevention. Participants will consume three different versions of broccoli extract supplements, with glucoraphanin amounts ranging from 35 to 70 mg. The supplements include Avmacol Extra Strength tablets and chewable wafers. Each participant will complete three separate 24-hour study cycles, ingesting one of the supplements during each cycle. During each study cycle, participants will provide blood and urine samples over 24 hours at specified time points to measure glucoraphanin, sulforaphane, and their metabolites. They will also follow diet restrictions, avoiding cruciferous vegetables and certain supplements for one week prior to and during each cycle. Researchers will monitor how these compounds are absorbed and excreted to understand their bioavailability.

Age: 18Years - 60YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating whether up to ten consecutive 24-hour treatments with the Selective Cytopheretic Device SCD can improve survival in patients with Acute Kidney Injury AKI who need continuous kidney replacement therapy CKRT. The study compares the use of SCD plus standard CKRT to CKRT alone to see if it reduces the need for long-term dialysis. This pivotal randomized controlled trial will include about 339 patients in intensive care units across 30 US sites. Participants will be assigned to one of two groups one group will receive up to ten 24-hour treatments using the SCD connected to their existing CKRT circuit along with standard care, while the other group will receive standard CKRT care alone. The SCD is a device designed to modulate inflammation by binding activated white blood cells during CKRT using regional citrate anticoagulation. Treatments occur sequentially over the study period. During the study, participants will be monitored for survival and dialysis dependency at 90 days, as well as dialysis dependence at 1 year, ICU-free days within the first 28 days, and mortality at 28 days. The trial includes assessments related to kidney function and patient outcomes over time. Participation involves regular monitoring during ICU care, with results informing the safety and effectiveness of adding SCD therapy to standard CKRT. The study is expected to continue until June 2027.

Age: 18Years +All GendersPhase Not Applicable
36 locations
C

Actively Recruiting

Researchers are investigating treatments for patients with metastatic bone disease affecting the proximal femur, a common site of cancer spread to the skeleton that impacts mobility and quality of life. This randomized controlled trial compares two surgical approaches to stabilize or replace the affected hip bone, aiming to find out whether removing and reconstructing the bone leads to better patient outcomes than using metal hardware for stabilization. Participants will be randomly assigned to one of two treatment groups one group will receive internal fixation using metal rods, plates, or screws to stabilize the bone, while the other group will undergo resection of the affected bone followed by endoprosthetic reconstruction, which may include hip replacement. Surgical specifics such as the type of implant, approach, and use of additional disease control methods will be decided by the surgeon. This trial explores whether the more invasive reconstruction surgery reduces cancer recurrence and mechanical failure compared to internal fixation. During the study, participants will have follow-up visits at 2 weeks, 6 weeks, 4 months, 6 months, 9 months, and 12 months after surgery to monitor their progress. Researchers will assess mortality, physical function, and days spent at home over one year following surgery, along with quality of life measures. These evaluations will help determine which surgical method provides better outcomes for patients living longer with metastatic bone disease.

Age: 18Years +All GendersPhase Not Applicable
13 locations

1-10 of 17

1